|
■ Run 28,
General module, is closed for protocol submission by
13th January 2010. The protocol for man be used for
correction of previously submitted protocols. |
|
■ The
results
of Run 27, B8
and pilot C2 are available as of 7th
December: Go to Newsletter for
a short summary of general results and access to the
complete general results.
Individual results are e-mailed to the participants
as of 7th December. |
|
■ Run B9,
Breast
cancer module, opens by 1st April (together with run
29 in General module). B9 now includes HER-2 CISH/SISH
(but not FISH). |
|
■ Markers (tests)
included 2010:
Go to
Participation:
General module
and Breast
cancer module. |
|
■ New participants: Go to
Participation for enrolment. The fees
for 2010 are stated in
Subscription. |
|
■ NordiQC Workshop: For programme 2010 Click on
Seminars. |
Figure: Proportion of labs
with sufficient
HER-2 IHC staining results in the latest four runs.
The FDA approved
kits, espc. Pathway (Ventana), have shown to
be robust, while in-house systems generally show
a poor performance. It is not acceptable that labs make
their own protocols unless they can prove a
performance comparable to the FDA approved kits. |
